Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 28

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 28
---
 appearing at the end of this prospectus. We believe the risks described below are the risks that are material to us as of the date of this prospectus. If any of the following risks actually occur, our business, results of operations and financial condition would likely be materially and adversely affected. In these circumstances, the market price of our securities could decline, and you may lose part or all of your investment. Risks Related to the Keystone Equity Financing It is not possible to predict the actual number of shares of our Common Stock, if any, we will sell under the Keystone Purchase Agreements, or the actual gross proceeds resulting from those sales or the dilution to you from those sales. Further, we may not have access to the full amount available under the Keystone Purchase Agreements. Pursuant to the Keystone Purchase Agreements, Keystone shall purchase from us up to $25.0 million of shares (the “Keystone Commitment Amount”). As of the date of this prospectus, we have issued and sold 112,274 shares of Common Stock for aggregate proceeds of $7,509,103 pursuant to the Keystone Equity Financing, which includes 11,690 shares of Common Stock pursuant to the February 2024 Keystone Purchase Agreement, and 100,584 shares of Common Stock pursuant to the November 2024 Keystone Purchase Agreement. The shares of our Common Stock that may be issued under the Keystone Purchase Agreements may be sold by us to Keystone at our discretion from time to time from the applicable Keystone Commencement Date until the earliest to occur of (i) the 36-month anniversary of the effective date of the applicable Registration Statement (as defined below), (ii) the date on which Keystone has purchased the Keystone Commitment Amount pursuant to the Keystone Purchase Agreements, (iii) the date on which our Common Stock fails to be listed or quoted on Nasdaq or any successor Eligible Market (as defined in the Keystone Purchase Agreements), and (iv) the date on which, pursuant to or within the meaning of any bankruptcy law, a custodian is appointed for us or for all or substantially all of our property, or we make a general assignment for the benefit of our creditors (each, a “Termination Event”). We generally have the right to control the timing and amount of any sales of our Common Stock to Keystone under the Keystone Purchase Agreements. Sales of our Common Stock, if any, to Keystone under the Keystone Purchase Agreements will depend upon market conditions and other factors to be determined by us. We may ultimately